The cellular regulatory protein p53 is mutated in up to one half of breast cancers. The alterations in p53 are generally single point mutations, which often result in over-expression of the mutant molecule in cancer cells. These mutations are not characteristically found in the regions of p53 bearing immunogenic peptides which bind to human (Hu) HLA A2.1. As a consequence of over-expression of mutant p53, the unaltered HLA A2.1 binding epitopes of p53 are also over-expressed, which makes them an attractive target for cellular immunotherapy. Unfortunately, previous investigators have failed to derive Hu p53-specific CTL which recognize full length p53 by in vitro immunization of Hu PBL. The proposed approach utilizes the generation of a xenogencic response against Hu p53 by a murine (Mu) transgenic model expressing the Hu HLA A2.l transplantation antigen. Mu CTL reactive against HLA A2.l binding peptides from Hu p53 will be derived by subcutaneous immunization along with adjuvant. The magnitude of the immune response will be measured against Hu p53 peptide primed or full length mutant p53 expressing Hu HLA A2.1+ target cells. Since the AA sequence of Mu and Hu p53 is conserved, it is likely that the highest affinity Mu CTL against p53 may be neonatally thymically deleted. To evaluate that hypothesis, CTL will also be derived from mice transgenic for HLA A2.l and knockout for Mu p53 (p53K0). Affinity of CTL derived from p53K0 mice for Hu mutant p53 expressing tumor cell lines will be compared to CTL derived from mice expressing Mu p53. p53K0 mice should not have been tolerized to p53, and should not have deleted high affinity p53 speciflc T cell receptors (TCR). Using PCR cloning techniques, the TCRs from high affinity T cell clones will be isolated. High affinity TCRs will be engineered into single chain TCR molecules, and introduced into naive T cells of the CD4 and CD8 subsets. The transduced T cells will be tested for their ability to kill HLA A2.l+, Hu p53 over-expressing, tumor cells in vitro and in in vivo tumor models. To address the possibility of generating autoimmunity, an autologous Mu p53 immunotherapy model wills-be generated. Mu p53 specific CTL will be derived, and the specificity for tumor as opposed to recognition of normal cells by molecularly cloned high affinity TCR transferred to naive Mu CTL will be tested in an in vivo Mu model. The ability to prevent carcinogen induced p53 over- expressing tumors will also be assessed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA070819-04
Application #
6173259
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Hecht, Toby T
Project Start
1997-07-10
Project End
2002-06-30
Budget Start
2000-07-01
Budget End
2001-06-30
Support Year
4
Fiscal Year
2000
Total Cost
$100,640
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Hardwick, Nicola R; Carroll, Mary; Kaltcheva, Teodora et al. (2014) p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. Clin Cancer Res 20:4459-70
Daftarian, Pirouz; Song, Guang-Yun; Ali, Saima et al. (2004) Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res 64:5407-14
Espenschied, Jonathan; Lamont, Jeffrey; Longmate, Jeff et al. (2003) CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 170:3401-7
Liu, X; Peralta, E A; Ellenhorn, J D et al. (2000) Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells. Cancer Res 60:693-701
Schwarz, R E; McCarty, T M; Peralta, E A et al. (1999) An orthotopic in vivo model of human pancreatic cancer. Surgery 126:562-7
Peralta, E A; Liu, X; McCarthy, T M et al. (1999) Immunotherapy of bladder cancer targeting P53. J Urol 162:1806-11
McCarty, T M; Liu, X; Sun, J Y et al. (1998) Targeting p53 for adoptive T-cell immunotherapy. Cancer Res 58:2601-5